Market Coverage
Institutional monitoring of immunotherapy & oncology assets.
ATNM Under Review
Actinium Pharmaceuticals
$32.8M
Q2 2027
Iomab-B — Phase 3 (Post-CRL)
ARQT Active
Arcutis Biotherapeutics
$2.76B
Cash Flow Positive (Q4 2025)
ZORYVE (Roflumilast) Cream 0.3% — sNDA Submitted
CCCC Active
C4 Therapeutics
$262.5M
Mid-2027
Cemsidomide (CFT7455) — Phase 2 (MOMENTUM)
RADX Watching
Radiopharm Theranostics
$48.9M
Q1 2027
RAD 101 (Pivalate) — Phase 2b
VIR Active
Vir Biotechnology
$1.43B
Q2 2028
VIR-5500 — Phase 1 (Updating to Pivotal)
ZNTL Active
Zentalis Pharmaceuticals
$184.2M
Late 2027
Azenosertib (ZN-c3) — Phase 2 (DENALI)